EGFR变异体的体内功能鉴定揭示胶质母细胞瘤的新驱动因素
研究采用自体原位的体内筛选方法鉴定驱动性EGFR变异体,发现A289I为最强效且此前未表征的变异体。A289I通过MTTP改变细胞三酰甘油促进胶质瘤发生,敲除Mttp可减少多种模型中的胶质瘤发生。
要点
- 体内筛选鉴定A289I为最强效EGFR变异体,此前未被表征。
- A289I通过MTTP改变三酰甘油促进胶质瘤发生。
- 小鼠胶质瘤中敲除Mttp可在多种模型中减少胶质瘤发生。
核心结论
- 相差单个氨基酸残基的EGFR变异体差异性地促进胶质瘤发生。
- 驱动胶质瘤生长的机制包括通过MTTP的脂质代谢。
- 理解三酰甘油蓄积可能为该致命疾病提供前瞻性治疗路径。
研究设计与样本
- 采用自体原位的体内筛选方法鉴定驱动性EGFR变异体。
- 通过RNA-Seq鉴定不同EGFR变异体小鼠胶质瘤的独特分子特征。
- 通过非偏倚脂质组学筛选进一步验证脂质代谢改变。
主要发现
- 筛选鉴定A289I为最强效EGFR变异体,此前未被表征。
- A289I通过MTTP改变细胞三酰甘油促进胶质瘤发生。
- 小鼠胶质瘤中敲除Mttp可在多种模型中减少胶质瘤发生。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma is the most common and aggressive primary brain tumor. Large-scale sequencing initiatives have cataloged its mutational landscape in hopes of elucidating mechanisms driving this deadly disease. However, a major bottleneck in harnessing this data for new therapies is deciphering "driver" and "passenger" events amongst the vast volume of information. METHODS: We utilized an autochthonous, in vivo screening approach to identify driver, EGFR variants. RNA-Seq identified unique molecular signatures of mouse gliomas across these variants, which only differ by a single amino acid change. In particular, we identified alterations to lipid metabolism, which we further validated through an unbiased lipidomics screen. RESULTS: Our screen identified A289I as the most potent EGFR variant, which has previously not been characterized. One of the mechanisms through which A289I promotes gliomagenesis is to alter cellular triacylglycerides through MTTP. Knockout of Mttp in mouse gliomas, reduces gliomagenesis in multiple models. CONCLUSIONS: EGFR variants that differ by a single amino acid residue differentially promote gliomagenesis. Among the identified mechanism that drives glioma growth include lipid metabolism through MTTP. Understanding triacylglyceride accumulation may present a prospective therapeutic pathway for this deadly disease.
引用
- Yu K, Kong K, Lozzi B, et al. In vivo functional characterization of EGFR variants identifies novel drivers of glioblastoma. Neuro Oncol. 2023. PMID: 36044040. doi:10.1093/neuonc/noac215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。